# Atlas Venture Life Science Advisors, LLC: Form 13F holdings

An institutional investment manager in CAMBRIDGE, MA. SEC CIK 1917529.

- Quarter ended: 2026-06-30
- Filed: 2026-08-13
- Reported value: $881.3m
- Positions: 7 (7 lines in the filing's table; lines for the same security and option type are added together here)
- Compared with: the 13F for the quarter ended 2026-03-31
- Filing: https://www.sec.gov/Archives/edgar/data/1917529/000110465926095933/

## Holdings

As filed, largest first. Reported value is what the manager stated at the quarter end (Jun 30, 2026), in US dollars; it is filing data, not a price. Weight is the share of the total reported value.

| Issuer | Class | Reported value | Weight | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | ---: | --- | --- |
| [Kymera Therapeutics, Inc. (KYMR)](/companies/kymr.md) | Common Stock | $326.5m | 37.1% | 2,847,541 |  | Reduced −1,730,467 |
| [Dyne Therapeutics, Inc. (DYN)](/companies/dyn.md) | Common Stock | $151.0m | 17.1% | 6,800,099 |  | Reduced −2,330,366 |
| [Sionna Therapeutics, Inc. (SION)](/companies/sion.md) | Common Stock | $131.8m | 15.0% | 2,995,602 |  | Unchanged |
| [Kailera Therapeutics, Inc. (KLRA)](/companies/klra.md) | Common Stock | $113.9m | 12.9% | 5,171,282 |  | New +5,171,282 |
| [Disc Medicine, Inc. (IRON)](/companies/iron.md) | Common Stock | $110.7m | 12.6% | 1,513,875 |  | Unchanged |
| [Q32 Bio, Inc. (QTTB)](/companies/qttb.md) | Common Stock | $34.6m | 3.9% | 2,717,106 |  | Added +625,000 |
| [Korro Bio, Inc. (KRRO)](/companies/krro.md) | Common Stock | $12.7m | 1.4% | 962,884 |  | Reduced −174,265 |

Source: SEC EDGAR, Form 13F-HR, accession 0001104659-26-095933. Last ingested by Listed: Oct 22, 2026, 05:26 ET. No prices; not investment advice.